- Feb 14, 2020
- 1,630
- Tinnitus Since
- 1-2019
- Cause of Tinnitus
- 20+ Years of Live Music, Motorcycles, and Power Tools
Have you watched the R&D event video / read the November investor deck? I think they did a good job of bringing all the data together from the single dose trials; and highlighted a lot of lessons learned in trial design AND got more specific on patient target for FX-322. When looking at the trials individually, yeah, it's underwhelming, and you can tell they have struggled to fine tune their recruiting; but in aggregate, it does start to make sense the signal they're seeing, and how FX-345 can build on the learnings.Question: I thought the delivery method is what decides how deep any drug can penetrate, not the drug itself?
I'm happy Frequency Therapeutics is pushing forward, but looking at recent history, they have proven to be way better at talking the talk than walking the walk. Sure, good communication is advantageous, especially when it comes to keeping the money coming in, but at some point I hope there will be some properly potent, concrete results also from the medical side.
This science is young (PCA), and this is how they learn to get it to market + iterate it. We're seeing it happen in real-time.
If you haven't I would encourage that you take the hour or so and watch it.
https://investors.frequencytx.com/2021_Virtual_R-D_Event